Welcome to Cangene

Cangene is a fully integrated developer and manufacturer of immune therapeutics, primarily targeting infectious disease, hematology, transplantation and biodefense applications. Four of our hyperimmune products have been approved in the United States and/or Canada, and three products are included in the U.S. Strategic National Stockpile.

With the commercial introduction of our first drug, WinRho® SDF, in 1980, we have established a lengthy history and a solid track record. We have been listed on the Toronto Stock Exchange since 1991 under the symbol CNJ.

News
Share Price
CNJ.TO:
2.650
Change
0.00 (0.00%)
Volume
400
Jun 19, 2013, 12:09 PM EDT Quotes Delayed by 30 minutes